All In Biotech

Drug Trial Radar · NCT07577817

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.

A Phase 1, 3-Part, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of CTX001 in Healthy Adult Participants.

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Oct 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Cajal Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is testing CTX001 for certain conditions where the body does not have enough available iron or has difficulty storing or moving iron properly. The purpose of this study is to investigate any side effects that may happen with CTX001, how CTX001 is absorbed by and processed in the body, and how CTX001 affects iron levels in the blood when administered with or without iron and/or food.

Conditions

  • Anemia
  • Iron Deficiencies
  • Chronic Kidney Disease

Interventions

  • CTX001 With and Without IronDrug

    There are two treatment periods. In the first, CTX001 is administered as a single dose (tablet) by itself. In the second, CTX001 is administered as a single dose (tablet) with iron.

  • CTX001 With IronDrug

    There are two treatment periods. In one, CTX001 is administered as a single dose (tablet) with iron (tablet) following a high fat, high calorie meal. In the other, CTX001 is administered as a single dose (tablet) with iron (tablet) under fasting conditions.

  • CTX001 Multiple DoseDrug

    CTX001 (tablet) is administered daily for 7 consecutive days.

  • Placebo With and Without IronDrug

    There are two treatment periods. In the first, placebo is administered as a single dose (tablet) by itself. In the second, placebo is administered as a single dose (tablet) with iron.

  • Placebo With IronDrug

    There are two treatment periods. In one, placebo is administered as a single dose (tablet) with iron (tablet) following a high fat, high calorie meal. In the other, placebo is administered as a single dose (tablet) with iron (tablet) under fasting conditions.

  • Placebo Multiple DoseDrug

    Placebo (tablet) is administered daily for 7 consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug through the last study visit, approximately 15 days.
  2. Number of Participants with Serious TEAEsTime frame: From first dose of study drug through the last study visit, approximately 15 days.
  3. Number of Participants with Clinically Significant Changes in Physical ExaminationTime frame: From the first dose of study drug through the last study visit; approximately 15 days.
  4. Number of Participants with Clinically Significant Changes in Safety Laboratory ValuesTime frame: From first dose of study drug through last study visit, approximately 15 days.
  5. Number of Participants with Clinically Significant Changes in Vital SignsTime frame: From the first dose of study drug through the last study visit, approximately 15 days.
  6. Number of Participants with Clinically Significant Changes in ElectrocardiogramsTime frame: From the first dose of study drug through the last study visit, approximately 15 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Melbourne, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.